Skip to main content
. 2018 Oct 29;19(11):3378. doi: 10.3390/ijms19113378

Figure 6.

Figure 6

Antitumor activity of MSC in combination with irinotecan and docetaxel in nude mice bearing human head-and-neck cancer cells, FaDU and A253 (A), and radiation-treated A549 lung carcinoma (B). MSC was administered orally daily for seven days and concurrently with anticancer therapies administered on day seven [82].